Table 2.

Multivariable-adjusted hazard ratios for death in patients with rheumatoid arthritis^*

Variable	Model 1 (n = 1,634)	Model 2 (n = 1,453)
Age at baseline	1.06 (1.04–1.07)†	1.06 (1.04–1.08)†
Female sex	0.47 (0.23–0.95)†	0.58 (0.27–1.24)
White race versus other	1.10 (0.82–1.49)	1.29 (0.88–1.89)
BMI category
<20 kg/m2	3.12 (2.12–4.57)†	2.31 (1.50–3.57)†
20–25 kg/m2	Reference	Reference
>25–30 kg/m2	0.91 (0.67–1.23)	0.92 (0.66–1.29)
>30 kg/m2	0.87 (0.61–1.24)	0.74 (0.49–1.11)
Weight loss category
<1 kg/m2 loss	Reference	Reference
>1 kg/m2 loss	1.99 (1.53–2.59)†	1.81 (1.36–2.41)†
Current therapy
Methotrexate	0.58 (0.45–0.76)†	0.62 (0.46–0.82)†
Prednisone	1.37 (1.06–1.77)†	1.21 (0.91–1.63)
TNF inhibitor	0.76 (0.55–1.05)	0.85 (0.60–1.21)
Baseline comorbidities
Diabetes	1.41 (1.09–1.83)†	1.32 (0.98–1.77)
Cardiovascular disease	1.55 (1.21–1.98)†	1.57 (1.19–2.09)†
Chronic kidney disease	1.62 (1.12–2.35)†	1.41 (0.88–2.23)
Chronic lung disease	1.39 (1.09–1.77)†	1.10 (0.83–1.45)
Any malignancy	1.36 (1.06–1.73)†	1.59 (1.21–2.10)†
Active smoking	1.50 (1.09–2.05)†	1.44 (1.03–2.03)†
Natural log–transformed CRP	–	1.29 (1.14–1.46)†
MD-HAQ score	–	1.53 (1.22–1.90)†

^*Model 1 includes age, female sex, white race, current body mass index (BMI) category, weight loss over the previous interval (versus no weight loss), use of methotrexate, prednisone, or tumor necrosis factor (TNF) inhibitor, presence of diabetes, cardiovascular disease, chronic kidney disease, or malignancy, and active smoking (17,057 observations, 280 deaths, 8,101 person-years). Model 2 includes the variables in model 1 but with the addition of the natural log–transformed C-reactive protein (CRP) level and the Multidimensional Health Assessment Questionnaire (MD-HAQ) scores (13,844 observations, 222 deaths, 6,417 person-years). Values are the hazard ratio (95% confidence interval).

^†P <0.05.